GlassScriptPhysician profile
Frank Pitruzzello
NPI 1003820697
$5,889.16
in general payments reported to CMS, 2019-2025
56 companies · $988 in 2025
The $988 reported for 2025 was more than what 83% of Radiation Oncology providers received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $424 · 2020: $569 · 2021: $982 · 2022: $719 · 2023: $1,032 · 2024: $1,176 · 2025: $988.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,196.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,195.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $771.34 | 2019-2025 | Kisqali, Piqray |
| Astrazeneca Pharmaceuticals LP | $703.61 | 2019-2025 | Calquence, Imfinzi, Enhertu |
| Merck Sharp & Dohme LLC | $449.47 | 2019-2025 | Keytruda, Lynparza, Reblozyl |
| Incyte Corporation | $371.38 | 2020-2025 | Jakafi, Monjuvi, Pemazyre |
| Eisai INC. | $344.72 | 2021-2025 | |
| Janssen Biotech, INC. | $269.24 | 2019-2025 | Darzalex, Talvey, Tecvayli |
| Daiichi Sankyo INC. | $258.85 | 2019-2025 | Enhertu, Datroway |
| Amgen INC. | $239.85 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $211.38 | 2020-2025 | Libtayo |
| Genentech USA, INC. | $177.63 | 2023-2025 | Polivy, Lunsumio, Columvi |
| Astellas Pharma US INC | $139.37 | 2019-2023 | Xospata, Xtandi |
| Genzyme Corporation | $125.70 | 2021-2024 | |
| Lilly USA, LLC | $119.50 | 2021-2023 | Jaypirca, Verzenio |
| Tersera Therapeutics LLC | $102.57 | 2023-2025 | Zoladex |
| Puma Biotechnology, INC. | $98.71 | 2019-2024 |
Show all 56 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Frank Pitruzzello listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.